CWBR earnings
CohBar Inc. (CWBR) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer ImmunotherapyCombined company will operate under the name "TuHURA Biosciences, Inc." and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and webcast today, Tuesday, May 23rd at 8:30 AM ET MENLO PARK, Calif. and TAMPA, Fla. , May 23, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) ("CohBar" or the "company") and Morphogenesis, Inc. ("M
- CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate ProgressMENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. "I'm pleased with the team's performance during the third quarter of 2022 in advancing our top priorities, including improving the formulation of CB5138-3, our product candidate for IPF," stated Dr. Joseph Sarret, Chief Executive Officer. "We continue to operate the company i
- CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022MENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 third quarter financial results after the market closes on Tuesday, November 8, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: November 8, 2022Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio Dial-in U.
- CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate ProgressIND for CB5138-3 on track for second half of 2023 Conference call and webcast today at 5:00 p.m. ET, August 15, 2022 MENLO PARK, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the second quarter ended June 30, 2022 and highlighted recent corporate progress. "We remain excited about the opportunity for CB5138-3 and its potential to make a significant impact on the treatment of IPF. During the prior quarter, we continue
- CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022MENLO PARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 second quarter financial results after the market closes on Monday, August 15, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: August 15, 2022Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio Dial-in U.S.
- CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate ProgressMENLO PARK, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress. "I am optimistic about the year ahead and the opportunity we have at CohBar to develop therapies for difficult to treat, multi-factorial diseases. In 2022, we remain focused on execution and with a strong team in place, we are well positioned to advance our mitochondrial programs an
- CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022MENLO PARK, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 first quarter financial results after the market closes on Monday, May 16, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: May 16, 2022Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio - Dial-in U.S. and
- CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2021 fourth quarter and full year financial results after the market closes on Tuesday, March 29, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: March 29, 2022Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio
- CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021MENLO PARK, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its third quarter 2021 financial results after the market closes on Monday, November 15, 2021. Management will host a conference call at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: November 15, 2021Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio Dial-in U.S. and Canada: (844) 825-9789Dial-in International: (412) 317-5180Conference ID No.
- CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and ObesityCB4211 was well-tolerated and appeared safe with no serious adverse eventsRobust reductions in ALT and AST Reduction in glucose and trend towards body weight reductionCompany to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced topline results from the multi-center, randomized, double-blind, placebo-controlled Phase 1a/1b clinical study of CB4211, under development for nonalcoholic steatohepatitis (NASH) and obesity. The study met its primary endpoint showing
- CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021MENLO PARK, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its second quarter 2021 financial results after the market closes on Tuesday, August 10, 2021. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call and Slide Presentation: Date: August 10, 2021Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio Dial-in U.S. and Canada: (877) 300-8521Di